Full length article| Volume 111, P336-346, October 01, 2021

# SARS-CoV-2 infections in 165 countries over time

Open AccessPublished:September 02, 2021

## Highlights

• Understanding severe acute respiratory syndrome coronavirus(SARS-CoV-2) dynamics requires knowledge of the true number of infections.
• Reported case counts alone often poorly reflect the pandemic’s actual dynamics.
• The actual number of SARS-CoV-2 infections is estimated for 165 countries.
• These weekly resolved estimates span from early 2020 until June 25, 2021.
• These estimates are a valuable resource for further epidemiological analyses.

## Abstract

Background: Understanding the dynamics of the COVID-19 pandemic and evaluating the efficacy of control measures requires knowledge of the number of infections over time. This number, however, often differs from the number of confirmed cases because of a large fraction of asymptomatic infections and different testing strategies.
Methods: This study uses death count statistics, age-dependent infection fatality risks, and stochastic modeling to estimate the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among adults (aged 20 years or older) in 165 countries over time, from early 2020 until June 25, 2021. The accuracy of the approach is confirmed through comparison with previous nationwide seroprevalence surveys.
Results: The estimates presented reveal that the fraction of infections that are detected vary widely over time and between countries, and hence confirmed cases alone often yield a false picture of the pandemic. As of June 25, 2021, the nationwide cumulative fraction of SARS-CoV-2 infections (cumulative infections relative to population size) was estimated as 98% (95% confidence interval [CI] 93–100%) for Peru, 83% (95% CI 61–94%) for Brazil, and 36% (95% CI 23–61%) for the United States.
Conclusions: The time-resolved estimates presented expand the possibilities to study the factors that influenced and still influence the pandemic’s progression in 165 countries.

## Background

Accurate estimates of the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a population are needed to evaluate disease control policies and test strategies, determine the role of environmental factors, predict future disease spread, assess the risk of foreign travel, and determine vaccination needs (
• Nguimkeu P.
Why is the number of COVID-19 cases lower than expected in sub-saharan africa? a cross-sectional analysis of the role of demographic and geographic factors.
,
• Pearce N.
• Vandenbroucke J.P.
• VanderWeele T.J.
• Greenland S.
Accurate statistics on COVID-19 are essential for policy guidance and decisions.
). Even if a retreat of the pandemic seems within reach in many countries, the efficacy of control measures in 2020 and 2021 and the environmental, political, and societal factors that influenced the epidemic’s progression in each country will undoubtedly be the topic of scholarly work for years to come. Because of the existence of a large fraction of asymptomatic cases as well as variation in reporting, testing effort, and testing strategies (e.g., random versus symptom triggered) (
• Chow C.C.
• Chang J.C.
• Gerkin R.C.
• Vattikuti S.
Global prediction of unreported SARS-cov2 infection from observed COVID-19 cases.
), reported case counts cannot be directly converted to infection counts, and a comparison of confirmed case counts between countries is generally of limited informative value (
• Lachmann A.
• Jagodnik K.M.
• Giorgi F.M.
• Ray F.
Correcting under-reported COVID-19 case numbers: estimating the true scale of the pandemic.
). Large-scale seroprevalence surveys (e.g., using antibody tests) can yield information on the disease’s prevalence and cumulative number of infections in a population, either directly or using dynamical modeling (
• Larremore D.B.
• Fosdick B.K.
• Bubar K.M.
• Zhang S.
• Kissler S.M.
• Metcalf C.J.E.
• et al.
Estimating SARS-cov-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys.
). However, such surveys involve substantial financial and logistical challenges, and yield reliable prevalence estimates only near the periods covered by the surveys; prevalence estimates based on seroprevalence surveys are thus largely restricted to short periods (e.g.,
• Bogogiannidou Z.
• Vontas A.
• Kyritsi M.A.
• Nikoulis D.J.
• et al.
Repeated leftover serosurvey of SARS-cov-2 igg antibodies, greece, march and april 2020.
,
• Le Vu S.
• Jones G.
• Anna F.
• Rose T.
• Richard J.B.
• Bernard-Stoecklin S.
• et al.
Prevalence of SARS-cov-2 antibodies in france: results from nationwide serological surveillance.
,
• Merkely B.
• Szabó A.J.
• Kosztin A.
• Berényi E.
• Sebestyén A.
• C L.
• et al.
Novel coronavirus epidemic in the hungarian population, a cross-sectional nationwide survey to support the exit policy in hungary.
,
• Murhekar M.V.
• Bhatnagar T.
• Selvaraju S.
• Saravanakumar V.
• Thangaraj J.W.V.
• Shah N.
• et al.
SARS-cov-2 antibody seroprevalence in india, august–september, 2020: findings from the second nationwide household serosurvey.
).
In contrast to case reports, COVID-19-related death counts are generally regarded as less sensitive to testing effort and testing strategy (
• Flaxman S.
• Mishra S.
• Gandy A.
• Unwin H.J.T.
• Mellan T.A.
• Coupland H.
• et al.
Estimating the effects of non-pharmaceutical interventions on COVID-19 in europe.
,
• Lau H.
• Khosrawipour T.
• Kocbach P.
• Ichii H.
• Bania J.
• Khosrawipour V.
Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters.
,
• Lu F.S.
• Nguyen A.T.
• Davis J.T.
• Chinazzi M.
• Xiong X.
• et al.
Estimating the cumulative incidence of COVID-19 in the united states using four complementary approaches.
,
• Maugeri A.
• Barchitta M.
• Battiato S.
• Agodi A.
Estimation of unreported novel coronavirus (SARS-cov-2) infections from reported deaths: A susceptible–exposed–infectious–recovered–dead model.
), and fortunately most countries have established nationwide continuous reporting mechanisms for COVID-19-related deaths. Hence, in principle, knowing the infection fatality risk (IFR; the probability of death following infection with SARS-CoV-2) should permit the conversion of death counts to infection counts (
• Bohk-Ewald C.
• Dudel C.
• Myrskylä M.
A demographic scaling model for estimating the total number of COVID-19 infections.
,
• Flaxman S.
• Mishra S.
• Gandy A.
• Unwin H.J.T.
• Mellan T.A.
• Coupland H.
• et al.
Estimating the effects of non-pharmaceutical interventions on COVID-19 in europe.
,
• Lu F.S.
• Nguyen A.T.
• Davis J.T.
• Chinazzi M.
• Xiong X.
• et al.
Estimating the cumulative incidence of COVID-19 in the united states using four complementary approaches.
,
• Sánchez-Romero M.
• di Lego V.
• Prskawetz A.
• L. Queiroz B.
An indirect method to monitor the fraction of people ever infected with COVID-19: an application to the united states.
). The IFR of SARS-CoV-2, however, depends strongly on the host’s age, and hence the effective IFR of the entire population depends on the population’s age structure as well as the disease’s age distribution (
• Dowd J.B.
• Andriano L.
• Brazel D.M.
• Rotondi V.
• Block P.
• Ding X.
• et al.
Demographic science aids in understanding the spread and fatality rates of COVID-19.
). Indeed, it was shown that the age dependency of the IFR, the age-dependency of SARS-CoV-2 prevalence, and the age structure of the population are largely sufficient to explain variation in the effective IFR between countries (

Levin A.T., Hanage W.P., Owusu-Boaitey N., Cochran K.B., Walsh S.P., Meyerowitz-Katz G.. Assessing the age specificity of infection fatality rates for COVID-19: meta-analysis & public policy implications. 2020. Working paper 27597. National Bureau of Economic Research.

). This suggests that age-stratified death counts (or estimates thereof) should be used in conjunction with age-dependent IFRs to obtain an accurate estimate of infection counts. This approach has been successfully used to estimate SARS-CoV-2 prevalence over time in Europe until May 4, 2020, on the basis of reported age-stratified death counts (
• Flaxman S.
• Mishra S.
• Gandy A.
• Unwin H.J.T.
• Mellan T.A.
• Coupland H.
• et al.
Estimating the effects of non-pharmaceutical interventions on COVID-19 in europe.
). In principle, one could also first determine the “effective” IFR (integrated over all ages) for the entire population and combine that effective IFR with total (non-age-stratified) death counts to estimate infection rates. This approach was taken by
• Sánchez-Romero M.
• di Lego V.
• Prskawetz A.
• L. Queiroz B.
An indirect method to monitor the fraction of people ever infected with COVID-19: an application to the united states.
, who first estimated the effective IFR for various states in the United States on the basis of—among other factors—age-specific mortality data and then estimated the cumulative number of SARS-CoV-2 infections across the United States as of September 8, 2020. However, such an effective IFR is specific to the population for which it was estimated, and hence applying it to other countries—even if corrections are made for the local population age structure, which is possible in the framework of
• Sánchez-Romero M.
• di Lego V.
• Prskawetz A.
• L. Queiroz B.
An indirect method to monitor the fraction of people ever infected with COVID-19: an application to the united states.
—would fail to account for differences (or uncertainty) in the age distribution of infections or deaths.
Unfortunately, age-stratified and time-resolved death statistics are not readily available for many countries with insufficiently comprehensive reporting, thus preventing the direct adoption of the above-mentioned approaches (
• Flaxman S.
• Mishra S.
• Gandy A.
• Unwin H.J.T.
• Mellan T.A.
• Coupland H.
• et al.
Estimating the effects of non-pharmaceutical interventions on COVID-19 in europe.
,
• O’Driscoll M.
• Ribeiro Dos Santos G.
• Wang L.
• Cummings D.A.T.
• Azman A.S.
• Paireau J.
• et al.
Age-specific mortality and immunity patterns of SARS-cov-2.
). In cases where only total death counts (i.e., aggregated over all ages) are available, such as the ones disseminated by the World Health Organization, one needs to independently estimate the age distribution of deaths (or infections) to convert total death counts to infection counts.
• Bohk-Ewald C.
• Dudel C.
• Myrskylä M.
A demographic scaling model for estimating the total number of COVID-19 infections.
disaggregated nationwide total death counts on the basis of a previously determined global average age distribution of deaths to estimate SARS-CoV-2 infections in 10 countries up to July 23, 2020. However, using a global average age distribution of deaths ignores the fact that the age distribution of infections (and deaths) actually needs to be adjusted for each country’s population age structure, even if any given age group were to experience a similar exposure in each country. Furthermore, while the approaches used by
• Bohk-Ewald C.
• Dudel C.
• Myrskylä M.
A demographic scaling model for estimating the total number of COVID-19 infections.
and
• Sánchez-Romero M.
• di Lego V.
• Prskawetz A.
• L. Queiroz B.
An indirect method to monitor the fraction of people ever infected with COVID-19: an application to the united states.
can account for the average time lag between infection and death, they cannot account for its actual probability distribution and considerable spread around the mean (
• Linton N.M.
• Kobayashi T.
• Yang Y.
• Hayashi K.
• Akhmetzhanov A.R.
• Sm J.
• et al.
Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data.
), which further complicates the estimation of time-resolved infections from deaths. Lastly, all of the above-mentioned studies cover only an early portion of the pandemic (
• Bohk-Ewald C.
• Dudel C.
• Myrskylä M.
A demographic scaling model for estimating the total number of COVID-19 infections.
,
• Flaxman S.
• Mishra S.
• Gandy A.
• Unwin H.J.T.
• Mellan T.A.
• Coupland H.
• et al.
Estimating the effects of non-pharmaceutical interventions on COVID-19 in europe.
) or focus only on a single time point (
• Sánchez-Romero M.
• di Lego V.
• Prskawetz A.
• L. Queiroz B.
An indirect method to monitor the fraction of people ever infected with COVID-19: an application to the united states.
), and focus on a small number of countries (1–11).
This study addresses the above-mentioned challenges by leveraging information on the age distribution of SARS-CoV-2 infections from multiple countries with available age-stratified death reports to estimate the likely age-distribution of SARS-CoV-2 infections in other countries, while accounting for each country’s population age structure and for uncertainty due to additional unidentified factors. On the basis of these calibrations, national SARS-CoV-2 prevalences (cumulative number of infections, weekly new infections, and exponential growth rate) are estimated over time, while each country’s population age structure, the likely age distribution of infections, the age dependency of the IFR, and the variation in the time lag between infection and death are accounted for. The estimates are specific to adults aged 20 years or older, covering 165 countries from early 2020 until June 25, 2021. The estimates are largely consistent with data from multiple previously published nationwide seroprevalence surveys. Unless mentioned otherwise, in the following, “infection,” “death,” and “vaccination” refer exclusively to SARS-CoV-2 infections, COVID-19-related deaths, and full vaccination against SARS-CoV-2, respectively.

## Results and discussion

### Calibrating the age distribution of SARS-CoV-2 prevalence

To calculate infection counts solely from total (i.e., non-age-stratified) death counts, while accounting for the age dependency of the IFR and each country’s population age structure, independent estimates of the ratios of infection risks between age groups (i.e., the risk of infection in any one age group relative to any other age group) are needed. To determine the general distribution of age-specific infection risk ratios, this study analyzed weekly age-stratified COVID-19-related death reports from 15 countries around the world using a probabilistic model of Poisson-distributed time-delayed death counts (see “Methods” for details). Briefly, for any given country $c,$ any given week $w,$ and any given age group $g,$ the number of new infections during that week ($Ic,w,g$) is assumed to be approximately equal to $αc,gIc,w,rNc,g/Nc,r,$ where $r$ represents some fixed reference age group, $Nc,g$ is the population size of age group $g,$ and $αc,g$ is the relative risk of infection of an individual in age group $g$ compared with an individual in age group $r$. The expected number of deaths in each age group 4 weeks later (roughly the average time lag between infection and death;
• Linton N.M.
• Kobayashi T.
• Yang Y.
• Hayashi K.
• Akhmetzhanov A.R.
• Sm J.
• et al.
Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data.
), denoted $Dc,w+4,g,$ was assumed to be $Ic,w,gRg,$ where $Rg$ is the IFR for that age group. While $Rg$ could, in principle, also differ between countries, to date insufficient information is available for calibrating $Rg$ separately for each country (but see the discussion of caveats below). Age-specific IFRs were calculated beforehand by averaging multiple IFR estimates reported in the literature (

Levin A.T., Hanage W.P., Owusu-Boaitey N., Cochran K.B., Walsh S.P., Meyerowitz-Katz G.. Assessing the age specificity of infection fatality rates for COVID-19: meta-analysis & public policy implications. 2020. Working paper 27597. National Bureau of Economic Research.

,
• Linden M.
• Dehning J.
• Mohr S.B.
• Mohring J.
• Meyer-Hermann M.
• Pigeot I.
• et al.
The foreshadow of a second wave: an analysis of current COVID-19 fatalities in germany.
,
• O’Driscoll M.
• Ribeiro Dos Santos G.
• Wang L.
• Cummings D.A.T.
• Azman A.S.
• Paireau J.
• et al.
Age-specific mortality and immunity patterns of SARS-cov-2.
,
• Pastor-Barriuso R.
• Pérez-Gómez B.
• Hernán M.A.
• Pérez-Olmeda M.
• Yotti R.
• Oteo-Iglesias J.
• et al.
Infection fatality risk for SARS-cov-2 in community dwelling population of spain: nationwide seroepidemiological study.
,
• Rinaldi G.
An empirical estimate of the infection fatality rate of COVID-19 from the first italian outbreak.
,
• Salje H.
• Tran Kiem C.
• Lefrancq N.
• Courtejoie N.
• Bosetti P.
• Paireau J.
• et al.
Estimating the burden of SARS-cov-2 in france.
). This calibration thus accounts for the age structure of each country, the age distribution of the disease in each country, and the age-dependency of the IFR. A critical assumption of the model is that, in any given country, nationwide age-specific infection risks covary linearly between age groups over time (i.e., an increase of disease prevalence in one age group coincides with a proportional increase of prevalence in any other age group). This assumption is motivated by the observation that weekly nationwide death counts generally covary strongly linearly between age groups (Fig. 1A and Supplemental Figs. S1 and S2); the adequacy of this model is also confirmed in retrospect (see below). For each country, the infection risk ratios $αc,g$ (for all $g≠r$) and the weekly infections in the reference age group $Ic,w,r$ (one per week) were fitted to the age-stratified weekly death counts by a maximum-likelihood approach and under the assumption that weekly death counts follow a Poisson distribution. This stochastic model explained the data generally well, with observed weekly death counts almost always falling within the 95% confidence interval of the model’s predictions (Supplemental Fig. S3). This supports the initial assumption that infection risks covary approximately linearly between age groups over time and suggests that country-specific but time-independent infection risk ratios are largely sufficient to describe the age distribution of SARS-CoV-2 infections in a country and over time. For any given age group $g,$ the fitted infection risk ratios $αc,g$ differed between countries but were generally of the same order of magnitude (Fig. 1B). On the basis of this observation, and as explained in the next section, it thus seems possible to approximately estimate the number of infections in any other country on the basis of total death counts, the population’s age structure, and the pool of infection risk ratios $αc,g$ fitted above (accounting for the uncertainty in the latter due to unknown additional factors).

### Estimating infection counts over time

On the basis of the pool of fitted infection risk ratios, the same age-dependent IFRs as used above, the probability distribution of time lags between infection, disease onset, and death (
• Linton N.M.
• Kobayashi T.
• Yang Y.
• Hayashi K.
• Akhmetzhanov A.R.
• Sm J.
• et al.
Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data.
), and total (non-age-stratified) COVID-19-related death count reports disseminated by the World Health Organization, the weekly infection counts were estimated over time in each of 165 countries that met certain data quality criteria (details are provided in “Methods”). Briefly, for any given country $c,$ any given week $w,$ and any given set of relative infection risks $α1,α2,…,$ the total number of deaths during that week ($Dc,w$) was assumed to be Poisson distributed with expectation given by
$E{Dc,w}=∑k=LminLmaxIc,w−k,rδk∑gRgαgNc,gNc,r,$
(1)

where, as before, $Rg$ is the IFR for age group $g,$ $Nc,g$ is the population size of age group $g,$ $δk$ is the probability that a fatal infection will result in death after $k$ weeks, $Lmin$ and $Lmax$ are the minimum and maximum considered time lags (in weeks) between infection and death, and $Ic,w,r$ is the (a priori unknown) number of new infections in the reference age group $r$ during week $w$. For the second sum in Eq.  (1), only age groups of 20 years or older were considered (in 5-year intervals) because estimates of the infection risk ratios $αg$ were unreliable for younger ages (because of low death counts) and because deaths among people younger than 20 years were numerically negligible compared with the total number of deaths reported. The expected number of deaths in any given week depends on the number of infections in multiple previous weeks because of the variability of the time lag between infection and death (typically 2–6 weeks;
• Linton N.M.
• Kobayashi T.
• Yang Y.
• Hayashi K.
• Akhmetzhanov A.R.
• Sm J.
• et al.
Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data.
). Hence, the time series of observed weekly death counts ($Dc,1,Dc,2,…$) results from a convolution (“blurring”) of the weekly infections counts ($Ic,1,r,Ic,2,r,…$), making the estimation of the latter based on the former a classical deconvolution problem, similar to those known from electronic signal processing, financial time series analysis, or medical imaging (
• Mendel J.M.
Maximum-likelihood deconvolution.
,
• Wiener N.
Extrapolation.
). Put simply, deconvolution can be interpreted as an algebraic inversion of the operation of convolution, similar to inverting the matrix of a linear transformation. In contrast to estimation approaches based on fitting dynamical models (e.g., susceptible-infectious-recovered or susceptible-exposed-infectious-recovered models) (
• Baccini M.
• Cereda G.
• Viscardi C.
The first wave of the SARS-cov-2 epidemic in tuscany (italy): a SI2r2d compartmental model with uncertainty evaluation.
,
• Chow C.C.
• Chang J.C.
• Gerkin R.C.
• Vattikuti S.
Global prediction of unreported SARS-cov2 infection from observed COVID-19 cases.
,
• Maugeri A.
• Barchitta M.
• Battiato S.
• Agodi A.
Estimation of unreported novel coronavirus (SARS-cov-2) infections from reported deaths: A susceptible–exposed–infectious–recovered–dead model.
,
• Maugeri A.
• Barchitta M.
• Battiato S.
• Agodi A.
Modeling the novel coronavirus (SARS-cov-2) outbreak in sicily, italy.
), which assume a particular dynamical model for the epidemic’s growth and often require a priori knowledge of several model parameters to ensure identifiability, time series deconvolution methods typically do not assume any particular dynamical model. Dynamics-agnostic deconvolution methods, including the ones used here, can thus be applied to more complex epidemiological scenarios with no a priori knowledge of the possible dynamics. A major challenge in deconvolution is to avoid overfitting, which can introduce spurious fluctuations in the estimated infection counts. Here, for every country $c,$ the unknown $Ic,w,r$ were estimated by use of a deconvolution operation based on maximum likelihood. To avoid the risk of overfitting, infection counts were first estimated on a lower-resolution time grid, and then linearly interpolated onto a weekly grid (see “Methods” for details). The total number of new infections among people aged 20 years or older during week $w$ was estimated as $Ic,w=Ic,w,r∑gαgNc,g/Nc,r$. Cumulative (i.e., past and current) infection counts were calculated as incremental sums of the weekly infection count estimates. The epidemic’s exponential growth rate over time was subsequently calculated from the estimated weekly infection counts on the basis of a Poisson distribution model and using a sliding-window approach.
Depending on the particular choice of infection risk ratios, the above approach yielded different estimates for the weekly nationwide infection counts, the cumulative infection counts, and the exponential growth rates over time. Uncertainty in the true infection risk ratios in any particular country stemming from non-modeled additional factors was accounted for by random sampling from the full distribution of fitted infection risk ratios (i.e., obtained from the various calibration countries) multiple times, and calculation of confidence intervals of the predictions based on the obtained distribution of estimates. Estimated weekly and cumulative infection fractions (i.e., relative to population size) and exponential growth rates over time are shown for a selection of countries in Fig. 2 and Supplemental Figs. S4, S5, S6, S7, and S8. A comprehensive report of estimates for all 165 countries is provided as Supplemental File 6. Global color maps of the latest estimates for all 165 countries are shown in Fig. 3.
To assess the accuracy of the approach described above, the estimated cumulative infection fractions were compared with seroprevalence estimates from 22 previously published nationwide seroprevalence surveys across 14 countries (Supplemental Table S1) (
• Alharbi N.K.
• Alghnam S.
• Algaissi A.
• Albalawi H.
• Alenazi M.W.
• Albargawi A.M.
• et al.
Nationwide seroprevalence of SARS-cov-2 in saudi arabia.
,
• Anand S.
• Montez-Rath M.
• Han J.
• Bozeman J.
• Kerschmann R.
• Beyer P.
• et al.
Prevalence of SARS-cov-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study.
,
• Bogogiannidou Z.
• Vontas A.
• Kyritsi M.A.
• Nikoulis D.J.
• et al.
Repeated leftover serosurvey of SARS-cov-2 igg antibodies, greece, march and april 2020.
,
• Espenhain L.
• Tribler S.
• Jørgensen C.S.
• Holm Hansen C.
• Wolff Sönksen U.
• Ethelberg S.
Prevalence of SARS-cov-2 antibodies in denmark 2020: results from nationwide, population-based sero-epidemiological surveys.
,
• Hallal P.
• Hartwig F.
• Horta B.
• Victora G.D.
• Silveira M.
• Struchiner C.
• et al.
Remarkable variability in SARS-cov-2 antibodies across brazilian regions: nationwide serological household survey in 27 states.
,
• Le Vu S.
• Jones G.
• Anna F.
• Rose T.
• Richard J.B.
• Bernard-Stoecklin S.
• et al.
Prevalence of SARS-cov-2 antibodies in france: results from nationwide serological surveillance.
,
• Merkely B.
• Szabó A.J.
• Kosztin A.
• Berényi E.
• Sebestyén A.
• C L.
• et al.
Novel coronavirus epidemic in the hungarian population, a cross-sectional nationwide survey to support the exit policy in hungary.
,
• Murhekar M.
• Bhatnagar T.
• Selvaraju S.
• Saravanakumar V.
• Vivian Thangaraj J.
• et al.
Prevalence of SARS-cov-2 infection in india: Findings from the national serosurvey, may-june 2020.
,
• Murhekar M.V.
• Bhatnagar T.
• Selvaraju S.
• Saravanakumar V.
• Thangaraj J.W.V.
• Shah N.
• et al.
SARS-cov-2 antibody seroprevalence in india, august–september, 2020: findings from the second nationwide household serosurvey.
,
• Nah E.H.
• Cho S.
• Park H.
• Hwang I.
• Cho H.I.
Nationwide seroprevalence of antibodies to SARS-cov-2 in asymptomatic population in south korea: a cross-sectional study.
,
• Poljak M.
• Oštrbenk Valenčak A.
• Štrumbelj E.
• Maver Vodičar P.
• Vehovar V.
• Resman Rus K.
• et al.
Seroprevalence of severe acute respiratory syndrome coronavirus 2 in slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned.
,
• Pollán M.
• Pérez-Gómez B.
• Pastor-Barriuso R.
• Oteo J.
• Hernán M.A.
• Pérez-Olmeda M.
• et al.
Prevalence of SARS-cov-2 in spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
,
• Reicher S.
• Ratzon R.
• Ben-Sahar S.
• Hermoni-Alon S.
• Mossinson D.
• Shenhar Y.
• et al.
Nationwide seroprevalence of antibodies against SARS-cov-2 in israel.
,
• Snoeck C.J.
• Vaillant M.
• Abdelrahman T.
• Satagopam V.P.
• Turner J.D.
• Beaumont K.
• et al.
Prevalence of SARS-cov-2 infection in the luxembourgish population: the CON-VINCE study.
,
• Ward H.
• Atchison C.J.
• Whitaker M.
• Ainslie K.E.C.
• Elliott J.
• Okell L.C.
• et al.
Antibody prevalence for SARS-cov-2 in england following first peak of the pandemic: REACT2 study in 100,000 adults.
). Only surveys attempting to estimate nationwide seroprevalence in the general population (in particular, either using geographically or demographically stratified sampling or adjusting for sample demographics) were included. Agreement between model estimates and seroprevalence estimates was generally good: 16 of the 22 seroprevalence estimates (accounting for the associated 95% confidence interval and the period of the underlying survey) overlapped with the model’s 95% confidence intervals, with three nonoverlaps observed for Brazil, one for Spain, one for the United Kingdom, and one for France (Supplemental Fig. S4). When point estimates were compared (i.e., not accounting for confidence intervals), the relative differences (model estimate minus seroprevalence, divided by seroprevalence) were mostly in the 25–50% range, although particularly high relative differences were found for Brazil (170–180%), one time point in France (464%), and one time point in Greece (348%) (overview in Supplemental Table S1). Apart from the possibility of erroneous model predictions (discussed extensively below), it should be kept in mind that seroprevalence surveys themselves yield only estimates of the cumulative fraction of infected individuals with an associated uncertainty interval, and that this uncertainty interval need not always account for all sources of error. In particular, the deviations of the model from seroprevalence-based estimates may partly be because antibody concentrations in infected individuals (especially asymptomatic ones) can drop over time, rendering many of them seronegative (
• Bolotin S.
• Tran V.
• Osman S.
• Brown K.A.
• Buchan S.A.
• Joh E.
• et al.
SARS-cov-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline.
,
• La Marca A.
• Capuzzo M.
• Paglia T.
• Roli L.
• Trenti T.
• Nelson S.M.
Testing for SARS-cov-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays.
,
• Long Q.X.
• Tang X.J.
• Shi Q.L.
• Li Q.
• Deng H.J.
• Yuan J.
• et al.
Clinical and immunological assessment of asymptomatic SARS-cov-2 infections.
). Thus, previously infected individuals may not all be recognized as such. This would be consistent with the fact that in all cases of major disagreement between model predictions and seroprevalence estimates the former were greater than the latter. Furthermore, sensitivity and specificity estimates for antibody tests performed in the laboratory or claimed by manufactures need not always apply in a community setting (
• La Marca A.
• Capuzzo M.
• Paglia T.
• Roli L.
• Trenti T.
• Nelson S.M.
Testing for SARS-cov-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays.
), thus introducing biases in seroprevalence estimates despite nominal adjustments for sensitivity and specificity.

### Case counts alone can yield wrong impressions

Estimates of SARS-CoV-2 prevalence in a population can yield insight into the epidemic’s scale and growth dynamics that may not have been possible from reported cases alone. One reason is that the fraction of infections that is detected and reported differs greatly between countries and often varies greatly over time. Indeed, according to the present estimates, in most countries, reported case counts initially severely underestimated the actual number of infections and often did not properly reflect the progression of the epidemic, while in many countries more recent case reports capture a much larger fraction of infections and more closely reflect the epidemic’s dynamics (Figs. 2A–E and Supplemental Fig. S5). For example, in the United States, France, Sweden, Belgium, Spain, the United Kingdom, and many other European countries, reported cases reflected only a small fraction of infections occurring in spring 2020, while most subsequent infections were successfully detected. Nevertheless, in many countries, even recent reported case counts poorly reflect the actual dynamics of the epidemic. For example, recent reported cases in Afghanistan, Angola, Brazil, Ecuador, Egypt, Guatemala, and Iran severely underestimate the disease’s rapid ongoing growth, with nearly all infections remaining undetected or unreported (Fig. 4). Future investigations, enabled by the infection count estimates presented here, might be able to identify the main factors (e.g., political, financial, and organizational) driving the discrepancies between infections and reported cases, and might be able to suggest concrete steps to eliminate these discrepancies or correct for them.
The above observations imply that comparisons of the epidemic’s extent and progression between countries should preferably be done on the basis of infection or death counts, rather than reported cases alone (
• Flaxman S.
• Mishra S.
• Gandy A.
• Unwin H.J.T.
• Mellan T.A.
• Coupland H.
• et al.
Estimating the effects of non-pharmaceutical interventions on COVID-19 in europe.
,
• Sánchez-Romero M.
• di Lego V.
• Prskawetz A.
• L. Queiroz B.
An indirect method to monitor the fraction of people ever infected with COVID-19: an application to the united states.
). For example, as of June 25, 2021, the cumulative per-capita number of cases reported for the Czech Republic (16%) and Slovenia (12%) was much higher than for Paraguay (5.8%), Peru (6.3%), or Brazil (8.6%), while the median predicted cumulative infection fractions for the Czech Republic (52%) and Slovenia (38%) were much lower than for Paraguay (86%), Peru (98%; Fig. 2O), and Brazil (83%) (Supplemental Figs. S6 and S7). Similarly, as of June 25, 2021, the cumulative per-capita number of cases reported for the United States (10%) was much higher than for neighboring Mexico (2%), while the median predicted cumulative infection fraction for the United States (36%; Fig. 2L) was much lower than for Mexico (77%; Fig. 2M). These examples highlight the value of considering actual infection counts relative to population size when comparing the extent of the epidemic and its relationship to public policy between countries. Future investigations, enabled by the prevalence estimates presented here, may be able to identify concrete political, environmental, and socioeconomic factors influencing the epidemic’s growth.

### Caveats

The predictions presented here are subject to some important caveats. First, erroneous reporting of total COVID-19-related deaths will have a direct impact on the estimated infection counts. This caveat is particularly important for countries with less developed medical or reporting infrastructure (
• Bastos S.B.
• Morato M.M.
• Cajueiro D.O.
• Normey-Rico J.E.
The COVID-19 (SARS-cov-2) uncertainty tripod in brazil: assessments on model-based predictions with large under-reporting.
,
• Feyissa G.T.
• Tolu L.B.
• Ezeh A.
Covid-19 death reporting inconsistencies and working lessons for low- and middle-income countries: opinion.
,
• Galvêas D.
• Barros F.
• Fuzo C.A.
A forensic analysis of SARS-cov-2 cases and COVID-19 mortality misreporting in the brazilian population.
,
• Lloyd-Sherlock P.
• Sempe L.
• McKee M.
• Guntupalli A.
Problems of data availability and quality for COVID-19 and older people in low- and middle-income countries.
,
• Natashekara K.
COVID-19 cases in india and kerala: a benford’s law analysis.
,
• Veiga e Silva L.
• de Andrade Abi Harb M.D.P.
• Teixeira Barbosa dos Santos A.M.
• de Mattos Teixeira C.A.
• Macedo Gomes V.H.
• Silva Cardoso E.H.
• et al.
Covid-19 mortality underreporting in brazil: Analysis of data from government internet portals.
), as well as for countries where reports may be censored or modified for political reasons (
• Kilani A.
An interpretation of reported COVID-19 cases in post-soviet states.
,
• Kobak D.
Excess mortality reveals COVID’s true toll in russia.
). A general underreporting of total COVID-19-related deaths, as has been suspected, for example, for Brazil (
• Bastos S.B.
• Morato M.M.
• Cajueiro D.O.
• Normey-Rico J.E.
The COVID-19 (SARS-cov-2) uncertainty tripod in brazil: assessments on model-based predictions with large under-reporting.
,
• Veiga e Silva L.
• de Andrade Abi Harb M.D.P.
• Teixeira Barbosa dos Santos A.M.
• de Mattos Teixeira C.A.
• Macedo Gomes V.H.
• Silva Cardoso E.H.
• et al.
Covid-19 mortality underreporting in brazil: Analysis of data from government internet portals.
), Italy (
• Ciminelli G.
• Garcia-Mandicó S.
Covid-19 in italy: an analysis of death registry data.
), Turkey (
• Kisa S.
• Kisa A.
Under-reporting of COVID-19 cases in turkey.
), India (
• Chatterjee P.
Is india missing COVID-19 deaths?.
), and Nigeria (
• Ohia C.
• Bakarey A.S.
Covid-19 and nigeria: putting the realities in context.
), would lead to a roughly proportional underestimation of infections. Similarly, inconsistencies between countries and over time in the classification of the causes of death also have the potential to alter model predictions (
• Feyissa G.T.
• Tolu L.B.
• Ezeh A.
Covid-19 death reporting inconsistencies and working lessons for low- and middle-income countries: opinion.
,
• França E.B.
• Ishitani L.H.
• Teixeira R.A.
• DMXd A.
• Corrêa P.R.L.
• Marinho F.
• et al.
Deaths due to COVID-19 in brazil: how many are there and which are being identified?.
,
• Leon D.A.
• Shkolnikov V.M.
• Smeeth L.
• Magnus P.
• Pechholdová M.
• Jarvis C.I.
COVID-19: a need for real-time monitoring of weekly excess deaths.
,
• Singh B.
International comparisons of COVID-19 deaths in the presence of comorbidities require uniform mortality coding guidelines.
). For example, it was pointed out that the United States and Russia tend to use rather different criteria for identifying COVID-19 as the underlying cause of death, while Kyrgyzstan and Kazakhstan modified their criteria several months into the pandemic (
• Singh B.
International comparisons of COVID-19 deaths in the presence of comorbidities require uniform mortality coding guidelines.
). Underreporting of COVID-19-related deaths may also explain why in some rare instances the number of reported positive cases substantially exceeds the estimated number of infections (e.g., for Singapore; Supplemental File 6). Comparisons of results between countries should thus be done with care. In countries where COVID-19-related deaths are suspected of being grossly misreported, excess death rates may provide an alternative means for obtaining accurate COVID-19-related death counts in future analyses (
• Azofeifa A.
• Valencia D.
• Rodriguez C.J.
• Cruz M.
• Hayes D.
• Montañez Báez E.
• et al.
Estimating and characterizing COVID-19 deaths, puerto rico, march–july 2020.
,
• Beaney T.
• Clarke J.M.
• Jain V.
• Golestaneh A.K.
• Lyons G.
• Salman D.
• et al.
Excess mortality: the gold standard in measuring the impact of COVID-19 worldwide?.
,
• Kobak D.
Excess mortality reveals COVID’s true toll in russia.
).
Second, systematic errors in the age-stratified death counts used for model calibration (obtained from the COVerAGE-DB database;
• Riffe T.
• Acosta E.
• team t.C.D.
Data resource profile: COVerAGE-DB: a global demographic database of COVID-19 cases and deaths.
) could impact model predictions. For example, a potentially more frequent erroneous attribution to alternative plausible causes of death (e.g., other respiratory disorders) in older patients could lead to a relative underreporting of COVID-19-related deaths in older age groups. Such an age bias would lead to an underestimation of the infection risk ratios $αc,g$ in older age groups, essentially shifting the estimated age distribution of infections towards younger age groups. If such erroneous calibrations are subsequently used to estimate infections from total death count data, this would lead to an overestimation of infections because the IFR is lower at younger ages (recall that the number of infections is approximately equal to the number of deaths divided by the IFR). Furthermore, while COVerAGE-DB is a rich and robust dataset, its age group harmonizations could, in principle, cause distortions in the age distribution of death counts. To assess whether these distortions are strong enough to substantially influence the model calibrations, in this study calibrations were repeated with an independent dataset of national age-stratified death counts, available for a subset of countries, from the French National Institute for Demographic Studies (INED). Across the two countries covered by both the INED and COVerAGE-DB and satisfying the same data criteria as in the earlier analyses, the infection risk ratios calibrated with the INED data were generally similar to those calibrated with the COVerAGE-DB data (Supplemental Fig. S9).
Third, even if all data were error-free, the infection risk ratios are calibrated on the basis of available age-stratified death statistics from a limited number of countries, and may not apply to all other countries (e.g., because of strong cultural differences). Uncertainty associated with this extrapolation is accounted for by considering infection risk ratios calibrated to multiple alternative countries from multiple continents (see “Methods”).
Fourth, governmental policies implemented at various time points could, in principle, change the infection risk ratios between age groups over time; for example, the opening and closing of schools and universities, or allowing or prohibiting visits to nursing homes. To assess the extent of this possible caveat, here the weekly death counts in each age group were compared with the total (age-integrated) weekly death counts over time (Supplemental Figs. S10 and S2). Age-specific and total death counts correlated strongly linearly over time in nearly all age groups and countries (Pearson correlation coefficient 0.5 or greater in almost all cases), suggesting that in any given country the proportion of infections per age group did not substantially vary over the course of the epidemic. Furthermore, the predictions of the fitted models (which assume time-independent infection risk ratios) were generally highly consistent with the age-stratified death counts (Supplemental Fig. S3), again suggesting that time-independent (but country-dependent and age-dependent) infection risk ratios provide a largely adequate model for the age distribution of infections.
Fifth, age-specific IFRs were obtained from studies in only a few countries (mostly Western) and often based on a small subset of closely monitored cases (e.g., from the Diamond Princess cruise ship). These IFR estimates may not be accurate for all countries, especially countries with a very different medical infrastructure, different sex ratios in the population, or a different prevalence of preexisting health conditions (e.g., diabetes), all of which can affect the IFR. That said, estimated trends over time within any given country, in particular exponential growth rates (e.g., Figs. 2P–T), are unlikely to be substantially affected by such biases if the biases remain relatively constant over time. For example, the exponential growth rates estimated here remained unchanged when alternative IFRs from the literature (

Levin A.T., Hanage W.P., Owusu-Boaitey N., Cochran K.B., Walsh S.P., Meyerowitz-Katz G.. Assessing the age specificity of infection fatality rates for COVID-19: meta-analysis & public policy implications. 2020. Working paper 27597. National Bureau of Economic Research.

,
• Linden M.
• Dehning J.
• Mohr S.B.
• Mohring J.
• Meyer-Hermann M.
• Pigeot I.
• et al.
The foreshadow of a second wave: an analysis of current COVID-19 fatalities in germany.
,
• O’Driscoll M.
• Ribeiro Dos Santos G.
• Wang L.
• Cummings D.A.T.
• Azman A.S.
• Paireau J.
• et al.
Age-specific mortality and immunity patterns of SARS-cov-2.
,
• Pastor-Barriuso R.
• Pérez-Gómez B.
• Hernán M.A.
• Pérez-Olmeda M.
• Yotti R.
• Oteo-Iglesias J.
• et al.
Infection fatality risk for SARS-cov-2 in community dwelling population of spain: nationwide seroepidemiological study.
,
• Rinaldi G.
An empirical estimate of the infection fatality rate of COVID-19 from the first italian outbreak.
,
• Salje H.
• Tran Kiem C.
• Lefrancq N.
• Courtejoie N.
• Bosetti P.
• Paireau J.
• et al.
Estimating the burden of SARS-cov-2 in france.
) were considered. To nevertheless examine the robustness of estimated SARS-CoV-2 prevalences against variations in the IFR, the above analyses were repeated with consideration for each age group of a set of multiple IFRs—that is, random sampling from the set of previously reported IFRs (

Levin A.T., Hanage W.P., Owusu-Boaitey N., Cochran K.B., Walsh S.P., Meyerowitz-Katz G.. Assessing the age specificity of infection fatality rates for COVID-19: meta-analysis & public policy implications. 2020. Working paper 27597. National Bureau of Economic Research.

,
• Linden M.
• Dehning J.
• Mohr S.B.
• Mohring J.
• Meyer-Hermann M.
• Pigeot I.
• et al.
The foreshadow of a second wave: an analysis of current COVID-19 fatalities in germany.
,
• O’Driscoll M.
• Ribeiro Dos Santos G.
• Wang L.
• Cummings D.A.T.
• Azman A.S.
• Paireau J.
• et al.
Age-specific mortality and immunity patterns of SARS-cov-2.
,
• Pastor-Barriuso R.
• Pérez-Gómez B.
• Hernán M.A.
• Pérez-Olmeda M.
• Yotti R.
• Oteo-Iglesias J.
• et al.
Infection fatality risk for SARS-cov-2 in community dwelling population of spain: nationwide seroepidemiological study.
,
• Rinaldi G.
An empirical estimate of the infection fatality rate of COVID-19 from the first italian outbreak.
,
• Salje H.
• Tran Kiem C.
• Lefrancq N.
• Courtejoie N.
• Bosetti P.
• Paireau J.
• et al.
Estimating the burden of SARS-cov-2 in france.
)—rather than consideration of their mean. Median model predictions remained nearly unchanged; however, the uncertainty (i.e., confidence intervals) of the estimates increased (examples in Supplemental Fig. S11).
Sixth, in countries where a large fraction of the population is now vaccinated, attention should be given to the limitations and interpretation of the model’s predictions for the recent periods of the pandemic. Indeed, while existing vaccines substantially reduce the probability of infection and death, none of them is 100% effective (
• Bermingham C.R.
• Morgan J.
• Ayoubkhani D.
• Glickman M.
• Islam N.
• Sheikh A.
• et al.
Estimating the effectiveness of first dose of COVID-19 vaccine against mortality in england: a quasi-experimental study.
,
• Calzetta L.
• Ritondo B.L.
• Coppola A.
• Matera M.G.
• Di Daniele N.
• Rogliani P.
Factors influencing the efficacy of COVID-19 vaccines: a quantitative synthesis of phase III trials.
,
• Soiza R.L.
• Scicluna C.
• Thomson E.C.
Efficacy and safety of COVID-19 vaccines in older people.
). Because the IFR may differ between vaccinated and unvaccinated individuals, conversion from death counts to infection counts using IFRs originally determined for unvaccinated people could lead to erroneous infection estimates. This error is relatively small if vaccinated people represent only a small fraction of new infections, which, given that vaccination substantially reduces the risk of infection, is probably the case in the many countries where most of the population is unvaccinated (as of June 25, 2021, 138 of 145 considered countries with available vaccination data; Supplemental File 6). To further assess the implications of vaccination on infection estimates, consider the following back-of-the-envelope calculation. Let $U$ be the ratio of vaccinated to unvaccinated individuals, let $Q$ be the risk of COVID-19-related death for a vaccinated individual relative to an unvaccinated one, and let $D˜$ and $D$ denote the number of deaths among vaccinated and unvaccinated individuals, respectively (country and week indices are omitted here for notational simplicity). We have $D˜/D≈QU,$ and hence the fraction of deaths attributed to vaccinated individuals is given by
$D˜D˜+D≈QUQU+1.$
(2)

As of June 25, 2021, in nearly all countries most of the population had not been fully vaccinated (hence $U<1$), exceptions being the Seychelles, Malta, Israel, Bahrain, Mongolia, Iceland, and Chile (where $U$ ranged between 1 and 2.2 on June 25, 2021). Field estimates for vaccine effectiveness against death generally range from 96.7% in Israel (
• Haas E.J.
• Angulo F.J.
• McLaughlin J.M.
• Anis E.
• Singer S.R.
• Khan F.
• et al.
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-cov-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in israel: an observational study using national surveillance data.
) to 98% in an Italian province (
• Flacco M.E.
• Soldato G.
• Acuti Martellucci C.
• Carota R.
• Di Luzio R.
• Caponetti A.
• et al.
Interim estimates of COVID-19 vaccine effectiveness in a mass vaccination setting: data from an italian province.
) and 98.7% in the United States (
• Vahidy F.S.
• Pischel L.
• Tano M.E.
• Pan A.P.
• Boom M.L.
• Sostman H.D.
• et al.
Real world effectiveness of COVID-19 mRNA vaccines against hospitalizations and deaths in the united states.
) among fully vaccinated individuals, corresponding to $Q$ in the range from 0.013 to 0.033. Hence, in nearly all countries (except the Seychelles, Malta, Israel, Bahrain, Mongolia, Iceland, and Chile) vaccinated individuals likely account for less than 3.2% of the reported deaths in recent months (up until June 25, 2021), and even less at earlier stages of the pandemic, where $U≪1$. The infection count estimates presented can thus be interpreted as approximately corresponding to the unvaccinated part of the population (e.g., an estimate of 1000 infections essentially means that among the unvaccinated population there were about 1000 infections), which in turn likely accounts for the vast majority of infections in most countries (as discussed above).

## Conclusions

This study presented estimates of the nationwide prevalence and growth rate of SARS-CoV-2 infections over time in 165 countries around the world based on official COVID-19-related death reports, age-specific IFRs, each country’s population age structure, and the probability distribution of time lags between infection and death. The complete report for all 165 countries is provided as Supplemental File 6. These estimates are also provided as machine-readable tables (Supplemental Files 1–5) for convenient downstream analyses; occasionally updated estimates are available at http://www.loucalab.com/archive/COVID19prevalence. Despite a variety of assumptions and caveats, the estimates presented are largely consistent with data from nationwide general-population seroprevalence surveys. The findings presented suggest that while in many countries the detection of infections has greatly improved, there are also numerous examples where even recent reported case counts do not properly reflect the epidemic’s dynamics. In particular, comparisons between countries based on infection counts can yield conclusions very different from those obtained from comparisons based merely on reported cases. The present work thus enables more precise assessments of the disease’s past and ongoing progression, evaluation and improvement of public interventions and testing strategies, and estimation of worldwide vaccination needs.

## Methods details

### Age-specific IFRs

Age-specific IFRs were calculated on the basis of the following literature:
• Pastor-Barriuso R.
• Pérez-Gómez B.
• Hernán M.A.
• Pérez-Olmeda M.
• Yotti R.
• Oteo-Iglesias J.
• et al.
Infection fatality risk for SARS-cov-2 in community dwelling population of spain: nationwide seroepidemiological study.
,

Levin A.T., Hanage W.P., Owusu-Boaitey N., Cochran K.B., Walsh S.P., Meyerowitz-Katz G.. Assessing the age specificity of infection fatality rates for COVID-19: meta-analysis & public policy implications. 2020. Working paper 27597. National Bureau of Economic Research.

,
• Salje H.
• Tran Kiem C.
• Lefrancq N.
• Courtejoie N.
• Bosetti P.
• Paireau J.
• et al.
Estimating the burden of SARS-cov-2 in france.
,
• Rinaldi G.
An empirical estimate of the infection fatality rate of COVID-19 from the first italian outbreak.
,
• O’Driscoll M.
• Ribeiro Dos Santos G.
• Wang L.
• Cummings D.A.T.
• Azman A.S.
• Paireau J.
• et al.
Age-specific mortality and immunity patterns of SARS-cov-2.
, and
• Linden M.
• Dehning J.
• Mohr S.B.
• Mohring J.
• Meyer-Hermann M.
• Pigeot I.
• et al.
The foreshadow of a second wave: an analysis of current COVID-19 fatalities in germany.
. For each age group considered, the average IFR across all of the aforementioned published IFRs was used, after linear interpolation where necessary (Supplemental Table S2).

### Calibrating age-specific infection risk ratios

The age-specific infection risk ratios were calibrated as follows. Age-specific population sizes for each country (status 2019) were downloaded from the United Nations website (https://population.un.org/wpp/Download/Standard/CSV) on October 23, 2020 (

DESA U.. World population prospects 2019 revision, online edition. Technical report; United Nations, Department of Economic and Social Affairs, Population Division; 2019. Https://population.un.org/wpp/.

). Time series of nationwide cumulative COVID-19-related death counts grouped by 5-year age intervals were downloaded on April 27, 2021, from COVerAGE-DB (https://osf.io/7tnfh), which is a database that gathers and curates official death count statistics from multiple official sources (
• Riffe T.
• Acosta E.
• team t.C.D.
Data resource profile: COVerAGE-DB: a global demographic database of COVID-19 cases and deaths.
). The last 7 days covered in the database were ignored to avoid potential biases caused by delays in death reporting. For each country included in COVerAGE-DB, and separately for each age group, it was ensured that cumulative death counts are nondecreasing (monotonic) over time by linear reinterpolation of death counts at problematic time points. To avoid inaccurate calibrations due to grossly problematic time series, any country for which the strongest violation in monotonicity (the largest decrease of cumulative deaths between any two time points for any age group considered) was greater than 1% of the maximum reported total cumulative deaths in that country (e.g., Canada) was omitted. For similar reasons, countries for which an interpolation was needed (either because of missing data or because of a violation of monotonicity) in any considered age group over a time span greater than 5 weeks (e.g., Iceland) were also omitted.
The remaining monotonized time series of cumulative deaths were linearly interpolated onto a regular weekly time grid (i.e., in which adjacent time points are 7 days apart); no extrapolation was performed (i.e., only dates between the first and last available data points were included). The weekly number of deaths in each age group was calculated as the difference in cumulative deaths between consecutive time points on the weekly grid. While some of the input time series are available at a daily resolution, a weekly discretization was chosen here (a) to reduce time series noise and (b) to “average out” the hard-to-model systematic variations in the epidemic’s dynamics between different days of the week (e.g., weekends vs. workdays). To ensure high accuracy of the calibrated infection risk ratios, only countries for which COVerAGE-DB covered at least 20 weeks with at least 100 reported deaths each were subsequently considered.
For each considered country $c,$ the “reference” age group $r$ was set to the age group that had the highest cumulative number of deaths. Designation of a reference group is done mostly for notational simplicity and consistency, so that age-specific prevalence ratios can all be defined relative to a common reference. For each other age group $g,$ the infection risk ratio $αc,g$ (i.e., the probability of an individual in group $g$ being infected relative to the probability of an individual in group $r$ being infected) was estimated by use of a probabilistic model. According to this model, the number of deaths in group $g$ during week $w$ (denoted $Dc,w,g$) was Poisson distributed with expectation
$Dc,w,r·αc,g·Nc,gNc,r·RgRr,$
(3)

where $Nc,g$ is the population size of age group $g$ in country $c,$ and $Rg$ is the IFR for age group $g$. Under this model, the maximum-likelihood estimate for $αc,g$ (i.e., given the weekly death count time series) is given by
$α^c,g=∑wDc,w,g∑wDc,w,rNc,rNc,g·RrRg.$
(4)

To avoid errors due to sampling noise, only weeks with at least 100 reported deaths were considered in the sums in Eq. (4). This threshold was chosen as a reasonable compromise between data quality (requiring more deaths per week implies less sampling noise) and data quantity (requiring fewer deaths per week increases the number of weeks available for calibration). Further increasing this threshold to 200 deaths per week generally had negligible effects on the results (see examples in Supplemental Fig. S12). Note that $αc,g$ might alternatively be estimated as the slope of the least-squares linear regression:
$Dc,w,g∼αc,gDc,w,r·Nc,gNc,r·Rc,gRc,r.$
(5)

Estimates obtained via linear regression were nearly identical to those obtained with use of the aforementioned Poissonian model, suggesting that the estimates are not very sensitive to the precise assumed distribution.
To evaluate the model’s adequacy (explained below), this study also estimated the weekly number of infections in the reference age group, $Ic,w,r,$ via maximum likelihood based on a probabilistic model in which $Dc,w,g$ was Poisson distributed with expectation
$E{Dc,w,g}=RgIc,w−4,rα^c,gNc,gNc,r.$
(6)

Under this model, the maximum-likelihood estimate for $Ic,w−4,r$ is given by
$I^c,w−4,r=Nc,r∑gDc,w,g∑gα^c,gRgNc,g.$
(7)

To evaluate the adequacy of the above stochastic model in explaining the original death count data, multiple hypothetical weekly death counts were simulated for each age group, and the distribution of simulated death counts was compared with the distribution of true death counts. Specifically, for each country $c,$ week $w,$ and age group $g,$ 100 random death counts ($D˜c,w,g$) were drawn from a Poisson distribution with expectation
$E{D˜c,w,g}=RgI^c,w−4,rα^c,gNc,gNc,r.$
(8)

Median simulated death counts and 50% and 95% equal-tailed confidence intervals, along with the original death counts, are shown for various countries and age groups in Supplemental Fig. S3, from which it can be seen that the model’s simulated time series are largely consistent with the original data.
In the subsequent analyses, only infection risk ratios $αc,g$ for which the corresponding linear curve (Eq. 5) achieved a coefficient of determination ($R2$) greater than 0.5 were used (shown in Fig. 1) to avoid less accurately estimated infection risk ratios (typically obtained from countries with low death rates). Infection risk ratios meeting this quality threshold cover 15 countries: Argentina, Bangladesh, Brazil, Colombia, the Czech Republic, Germany, the United Kingdom, Hungary, India, Mexico, Paraguay, Peru, the Philippines, Ukraine, and the United States.

### Estimating infection counts from total death counts

Time series of total (non-age-stratified) nationwide cumulative reported death and case counts were downloaded from the website of the World Health Organization (https://covid19.who.int/table) on July 20, 2021. The last 7 days covered in the database were ignored to avoid potential biases caused by delays in case and death reporting (
• Lipsitch M.
• Donnelly C.A.
• Fraser C.
• Blake I.M.
• Cori A.
• Dorigatti I.
• et al.
Potential biases in estimating absolute and relative case-fatality risks during outbreaks.
). Cumulative death and case counts were made nondecreasing and interpolated onto a weekly time grid as described above. Only countries that reported at least one death per week for at least 10 weeks were included in the analysis below. In addition, any country for which the strongest violation in monotonicity was greater than 1% of the maximum reported total cumulative deaths in that country, or for which an interpolation was needed (e.g., because of missing data) over a time span greater than 5 weeks (as done above for the COVerAGE-DB data), was omitted. For each country $c,$ each week $w,$ and any particular choice of age-specific infection risk ratios $α1,α2,…$ (uniquely covering all ages 20 years and older), the number of infections was estimated as follows. Let $N$ be the number of consecutive weeks for which total deaths are reported. Let $r$ denote some fixed reference age group relative to which infection risk ratios are defined (i.e., such that $αr=1$); here, ages 70–74 years were used as a reference. Let $δk$ denote the probability that a fatal infection will lead to death after $k$ weeks, where $k=Lmin,…,Lmax,$ where $Lmin$ is the minimum and $Lmax$ is the maximum time lag considered. Let $L:=Lmax−Lmin+1$. Let $Ic,w,r$ be the (a priori unknown) number of new infections occurring during week $w$ in the reference age group. The number of COVID-19-related deaths during week $w$ in age group $g,$ denoted $Dc,w,g,$ was assumed to be Poisson distributed with expectation given by
$E{Dc,w,g}=∑k=LminLmaxIc,w−k,rδkRgαgNc,gNc,r.$
(9)

The total number of deaths in week $w,$ $Dc,w,$ is thus Poisson-distributed with expectation
$E{Dc,w}=∑k=LminLmaxIc,w−k,rδk∑gRgαgNc,gNc,r.$
(10)

As explained earlier, only age groups 20 years and older were included because infection risk ratios could not be reliably estimated for younger ages and because the contribution of younger ages to total death counts can be considered numerically negligible. The $δk$ were calculated through 1,000,000 Monte Carlo simulations based on the log-normal distribution models fitted by
• Linton N.M.
• Kobayashi T.
• Yang Y.
• Hayashi K.
• Akhmetzhanov A.R.
• Sm J.
• et al.
Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data.
, Table 2) for the time lags between infection and disease onset and the time lags between disease onset and death, and under the assumption that the two time lags are independently distributed (see Supplemental Table S3). The minimum and maximum time lags considered were $Lmin=2$ weeks and $Lmax=6$ weeks because this range covers the bulk (approximately 90%) of cases and because further increasing $Lmax$ or decreasing $Lmin$ increases the width of the convolution kernel, thus increasing the risk of introducing spurious fluctuations in the estimated $Ic,w,r$. The considered $δLmin,…,δLmax$ were normalized to have sum 1 to maintain consistency with the total IFR (i.e., summed over all time lags).
Given the above model, the goal is to estimate the unknown weekly infection counts in the reference group, $Ic,w,r,$ from the recorded weekly death counts, $Dc,w$. This is a classical deconvolution problem because each $Dc,w$ results from the additive effects of infections from multiple preceding weeks (
• Mendel J.M.
Maximum-likelihood deconvolution.
,
• Wiener N.
Extrapolation.
). Eq. (10) can be written abstractly in matrix form:
$E{D}=K·I,$
(11)

where $K$ is a convolution matrix of size $N×(N+L−1),$
$K:=(δLmaxδLmax−1⋯δLmin00⋯00δLmax⋯δLmin+1δLmin0⋯000⋯δLmin+2δLmin+1δLmin⋯0⋮⋮⋮⋮⋮⋮00⋯000⋯δLmin)·∑gRgαgNc,gNc,r,$
(12)

$D$ is a column vector of size $N$ listing the reported weekly death counts $Dc,1,…,Dc,N,$ and $I$ is a column vector of size $N+L−1$ listing the unknown weekly infection counts $Ic,1−Lmax,r,…,Ic,N−Lmin,r$. For notational simplicity, the country index $c$ is omitted from $I,$ $D,$ and $K,$ but keep in mind that $I,$ $D,$ and $K$ refer to a specific country. It is straightforward to show that, under the above model, the log-likelihood of the observed weekly death counts ($D$) is given by
$lnL=∑w=1N[Dwln(KI)w−(KI)w−ln(Dw!)].$
(13)

In principle, one could estimate the unknown vector $I$ via maximum likelihood. Indeed, the above log-likelihood is maximized when the following condition is met:
$∑w=1NKwv=∑w=1NDwKwv(KI)w$
(14)

for all $v∈{1,…,N+L−1}$. A sufficient condition for Eq. (14) is that $KI=D$; in other words, any vector $I^$ satisfying $KI^=D$ is a maximum-likelihood estimate. Such an estimate can be obtained using the Moore-Penrose pseudoinverse of $K,$ denoted $K+$ (
• Moore E.H.
On the reciprocal of the general algebraic matrix.
,
• Penrose R.
A generalized inverse for matrices.
). Because $K$ has linearly independent rows, its pseudoinverse is $K+=KT(KKT)−1,$ and hence setting $I^:=K+D$ would satisfy $KI^=D$. However, because of known issues with inverting convolution matrices, such a naive estimation tends to introduce spurious fluctuations in the estimated $I$. One approach is to reduce the temporal resolution of the estimated $I,$ which effectively reduces the number of estimated free parameters (
• Louca S.
• Astor Y.M.
• Doebeli M.
• Taylor G.T.
• Scranton M.I.
Microbial metabolite fluxes in a model marine anoxic ecosystem.
). Hence, instead of estimating $Ic,w,r$ separately for each week, a coarser time grid was considered that has 4 times fewer time points than the original weekly time grid (i.e., such that the infection count $Ic,w,r$ is freely estimated only every fourth week), while assuming linear variation between these time points. This approach is a variant of constrained deconvolution using spline functions, pioneered by
• Verotta D.
Two constrained deconvolution methods using spline functions.
and reviewed by
• Godfrey K.R.
• Chappell M.J.
• Hovorka R.
• Bates R.A.
A comparison of six deconvolution techniques.
, using linear splines and maximizing the likelihood function (thus accounting for the Poisson model described above) rather than minimizing the sum of squared residuals (which assumes normally distributed data). For example, for an original weekly time series spanning 100 weeks, first the $Ic,w,r$ are estimated at about $100/4$ discrete time points, each 4 weeks apart, and then linear interpolation is used to obtain the remaining $Ic,w,r$. Denoting by $J$ the column vector listing the infection counts on this coarser time grid ($Ic,1−Lmax,r,Ic,1−Lmax+4,r,…$), and by $G$ the matrix mapping $J$ to $I$ via linear interpolation (i.e., $I=GJ$), one thus obtains the following log-likelihood in terms of $J$:
$lnL=∑w=1N[Dwln(KGJ)w−(KGJ)w−ln(Dw!)].$
(15)

The corresponding maximum-likelihood estimate $J^$ can no longer be obtained simply by solving the equation $KGJ^=D$ because this linear problem is overdetermined (i.e., it is unlikely that a $J^$ can be found such that $KGJ^=D$ is exactly satisfied). However, an optimally approximate solution (in the least-squares sense), $J˜,$ can be obtained by setting $J˜:=(KG)+D$. To determine the exact maximum-likelihood estimate $J^$—that is, the $J$ maximizing $lnL$ in Eq. (15)—numerical optimization was used, as implemented in the R function nloptr::nloptr, while the aforementioned approximation $J˜$ was used as a starting point. Subsequently setting $I^:=GJ^$ yielded an estimate for the weekly infections counts $Ic,w,r$. The corresponding total number of weekly infections, $I^c,w,$ can be calculated from the estimates $I^c,w,r$ as follows:
$I^c,w=I^c,w,r∑gαgNc,gNc,r.$
(16)

The corresponding cumulative number of total infections up until any given week can be obtained by summing the weekly infection counts.
Exponential growth rates over time were estimated from the weekly infection counts by a sliding-window approach, as follows. In every sliding window (spanning 5 consecutive weeks), an exponential function of the form $I(t)=Aetλ$ was fitted, where $t$ denotes the time in days and $A$ and $λ$ are unknown parameters (in particular, $λ$ is the exponential growth rate in that window). The parameters $A$ and $λ$ were fitted via maximum likelihood, assuming that the total number of weekly infections, $Ic,w,$ was Poisson distributed with expectation $Aetwλ$. Under this model, the log-likelihood of the data (more precisely, of the previously estimated weekly infection counts) is
$lnL=∑w[I^c,wlnA+I^c,wλtw−Aeλtw−ln(I^c,w!)],$
(17)

where $w$ refers to iteration over all weeks in the specific sliding window. The maximum-likelihood estimates of $A$ and $λ$ are obtained by solving $∂lnL/∂λ=0$ and $∂lnL/∂A=0,$ which quickly leads to the necessary condition
$∑weλ^tw∑gtweλ^tw·∑wtwI^c,w=∑wI^c,w.$
(18)

Eq. (18) was solved numerically by the bisection method to obtain the maximum-likelihood estimate $λ^$.
To assess estimation uncertainties stemming from sampling stochasticity and uncertainties in the infection risk ratios, the above estimations were repeated 100 times with use of alternative infection risk ratios (for each age group drawn randomly from the set of infection risk ratios previously fitted to various countries) and with replacement of the reported weekly death counts $Dc,w$ with values drawn from a Poisson distribution with mean $Dc,w$. Hence, rather than point estimates, all predictions are reported in the form of medians and equal-tailed confidence intervals. Tables of all estimates for all countries considered up until June 25, 2021, are provided in Supplemental Files 1–5; a visual report is provided as Supplemental File 6.

### Assessing the robustness of COVerAGE-DB-based calibrations

To examine whether the age harmonizations of COVerAGE-DB death counts had a major impact on the calibrated infection risk ratios ($αc,g$), the calibrations were also repeated with an independent dataset of national age-stratified death counts obtained from the French INED at https://dc-covid.site.ined.fr/en/data/pooled-datafiles (accessed July 20, 2021). Only countries also included in the calibrations described above and meeting the same data size and quality criteria were considered (the United States and Ukraine). Age groups $g$ not intersecting with at least one finite age interval in the INED database were also omitted from the comparison. Supplemental Fig. S9 shows the COVerAGE-DB-based and INED-based calibrated infection risk ratios across all countries and age groups considered; as can be seen, the two sets largely agree ($R2=0.92$), suggesting that COVerAGE-DB’s age harmonizations did not substantially compromise the model calibrations.

### Vaccination data

Data on nationwide completed vaccinations per country over time were obtained from the GitHub repository of the Johns Hopkins Centers for Civic Impact at https://github.com/govex/COVID-19/blob/master/data_tables/vaccine_data/global_data/time_series_covid19_vaccine_global.csv (accessed July 20, 2021). Cumulative vaccination counts were monotonized and interpolated onto a weekly time grid as described above for the death count data.

## Declarations

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Availability of data and materials

All data used in this article are publicly available at the locations described in the “Methods” section. SARS-CoV-2 prevalences over time, as predicted in this study, are available in Supplemental Files 1–5. A comprehensive visual report for all 165 countries is provided as Supplemental File 6.

### Competing interests

The author declares that he has no competing interests.

### Funding

The author was supported by a US National Science Foundation RAPID grant.

### Author’s contributions

The entire manuscript was prepared by the author.

## Acknowledgments

Not applicable.

## References

• Alharbi N.K.
• Alghnam S.
• Algaissi A.
• Albalawi H.
• Alenazi M.W.
• Albargawi A.M.
• et al.
Nationwide seroprevalence of SARS-cov-2 in saudi arabia.
J Infect Public Health. 2021; 14: 832-838
• Anand S.
• Montez-Rath M.
• Han J.
• Bozeman J.
• Kerschmann R.
• Beyer P.
• et al.
Prevalence of SARS-cov-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study.
Lancet. 2020; 396: 1335-1344
• Azofeifa A.
• Valencia D.
• Rodriguez C.J.
• Cruz M.
• Hayes D.
• Montañez Báez E.
• et al.
Estimating and characterizing COVID-19 deaths, puerto rico, march–july 2020.
Public Health Rep. 2021; 136: 354-360
• Baccini M.
• Cereda G.
• Viscardi C.
The first wave of the SARS-cov-2 epidemic in tuscany (italy): a SI2r2d compartmental model with uncertainty evaluation.
PLoS ONE. 2021; 16: e0250029
• Bastos S.B.
• Morato M.M.
• Cajueiro D.O.
• Normey-Rico J.E.
The COVID-19 (SARS-cov-2) uncertainty tripod in brazil: assessments on model-based predictions with large under-reporting.
Alex Eng J. 2021; 60: 4363-4380
• Beaney T.
• Clarke J.M.
• Jain V.
• Golestaneh A.K.
• Lyons G.
• Salman D.
• et al.
Excess mortality: the gold standard in measuring the impact of COVID-19 worldwide?.
J R Soc Med. 2020; 113: 329-334
• Bermingham C.R.
• Morgan J.
• Ayoubkhani D.
• Glickman M.
• Islam N.
• Sheikh A.
• et al.
Estimating the effectiveness of first dose of COVID-19 vaccine against mortality in england: a quasi-experimental study.
medRxiv. 2021; https://doi.org/10.1101/2021.07.12.21260385
• Bogogiannidou Z.
• Vontas A.
• Kyritsi M.A.
• Nikoulis D.J.
• et al.
Repeated leftover serosurvey of SARS-cov-2 igg antibodies, greece, march and april 2020.
Eurosurveillance. 2020; 25: 2001369
• Bohk-Ewald C.
• Dudel C.
• Myrskylä M.
A demographic scaling model for estimating the total number of COVID-19 infections.
Int J Epidemiol. 2020; 49: 1963-1971
• Bolotin S.
• Tran V.
• Osman S.
• Brown K.A.
• Buchan S.A.
• Joh E.
• et al.
SARS-cov-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline.
J Infect Dis. 2021; 223: 1334-1338
• Calzetta L.
• Ritondo B.L.
• Coppola A.
• Matera M.G.
• Di Daniele N.
• Rogliani P.
Factors influencing the efficacy of COVID-19 vaccines: a quantitative synthesis of phase III trials.
Vaccines. 2021; 9: 341
• Chatterjee P.
Is india missing COVID-19 deaths?.
Lancet. 2020; 396: 657
• Chow C.C.
• Chang J.C.
• Gerkin R.C.
• Vattikuti S.
Global prediction of unreported SARS-cov2 infection from observed COVID-19 cases.
medRxiv. 2020; https://doi.org/10.1101/2020.04.29.20083485
• Ciminelli G.
• Garcia-Mandicó S.
Covid-19 in italy: an analysis of death registry data.
J Public Health. 2020; 42: 723-730
1. DESA U.. World population prospects 2019 revision, online edition. Technical report; United Nations, Department of Economic and Social Affairs, Population Division; 2019. Https://population.un.org/wpp/.

• Dowd J.B.
• Andriano L.
• Brazel D.M.
• Rotondi V.
• Block P.
• Ding X.
• et al.
Demographic science aids in understanding the spread and fatality rates of COVID-19.
Proc Natl Acad Sci U S A. 2020; 117: 9696-9698
• Espenhain L.
• Tribler S.
• Jørgensen C.S.
• Holm Hansen C.
• Wolff Sönksen U.
• Ethelberg S.
Prevalence of SARS-cov-2 antibodies in denmark 2020: results from nationwide, population-based sero-epidemiological surveys.
medRxiv. 2021; https://doi.org/10.1101/2021.04.07.21254703
• Feyissa G.T.
• Tolu L.B.
• Ezeh A.
Covid-19 death reporting inconsistencies and working lessons for low- and middle-income countries: opinion.
Front Med. 2021; 8: 150
• Flacco M.E.
• Soldato G.
• Acuti Martellucci C.
• Carota R.
• Di Luzio R.
• Caponetti A.
• et al.
Interim estimates of COVID-19 vaccine effectiveness in a mass vaccination setting: data from an italian province.
Vaccines. 2021; 9: 628
• Flaxman S.
• Mishra S.
• Gandy A.
• Unwin H.J.T.
• Mellan T.A.
• Coupland H.
• et al.
Estimating the effects of non-pharmaceutical interventions on COVID-19 in europe.
Nature. 2020; 584: 257-261
• França E.B.
• Ishitani L.H.
• Teixeira R.A.
• DMXd A.
• Corrêa P.R.L.
• Marinho F.
• et al.
Deaths due to COVID-19 in brazil: how many are there and which are being identified?.
Rev Bras Epidemiol. 2020; 23: E200053
• Galvêas D.
• Barros F.
• Fuzo C.A.
A forensic analysis of SARS-cov-2 cases and COVID-19 mortality misreporting in the brazilian population.
Public Health. 2021; 196: 114-116
• Haas E.J.
• Angulo F.J.
• McLaughlin J.M.
• Anis E.
• Singer S.R.
• Khan F.
• et al.
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-cov-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in israel: an observational study using national surveillance data.
Lancet. 2021; 397: 1819-1829
• Hallal P.
• Hartwig F.
• Horta B.
• Victora G.D.
• Silveira M.
• Struchiner C.
• et al.
Remarkable variability in SARS-cov-2 antibodies across brazilian regions: nationwide serological household survey in 27 states.
medRxiv. 2020; https://doi.org/10.1101/2020.05.30.20117531
• Kilani A.
An interpretation of reported COVID-19 cases in post-soviet states.
J Public Health. 2021; 43: e409-e410
• Kisa S.
• Kisa A.
Under-reporting of COVID-19 cases in turkey.
Int J Health Plann Manage. 2020; 35: 1009-1013
• Kobak D.
Excess mortality reveals COVID’s true toll in russia.
Significance. 2021; 18: 16-19
• La Marca A.
• Capuzzo M.
• Paglia T.
• Roli L.
• Trenti T.
• Nelson S.M.
Testing for SARS-cov-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays.
Reprod Biomed Online. 2020; 41: 483-499
• Lachmann A.
• Jagodnik K.M.
• Giorgi F.M.
• Ray F.
Correcting under-reported COVID-19 case numbers: estimating the true scale of the pandemic.
medRxiv. 2020; https://doi.org/10.1101/2020.03.14.20036178
• Larremore D.B.
• Fosdick B.K.
• Bubar K.M.
• Zhang S.
• Kissler S.M.
• Metcalf C.J.E.
• et al.
Estimating SARS-cov-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys.
eLife. 2021; 10: e64206
• Lau H.
• Khosrawipour T.
• Kocbach P.
• Ichii H.
• Bania J.
• Khosrawipour V.
Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters.
Pulmonology. 2021; 27: 110-115
• Le Vu S.
• Jones G.
• Anna F.
• Rose T.
• Richard J.B.
• Bernard-Stoecklin S.
• et al.
Prevalence of SARS-cov-2 antibodies in france: results from nationwide serological surveillance.
Nat Commun. 2021; 12: 3025
• Leon D.A.
• Shkolnikov V.M.
• Smeeth L.
• Magnus P.
• Pechholdová M.
• Jarvis C.I.
COVID-19: a need for real-time monitoring of weekly excess deaths.
Lancet. 2020; 395: e81
2. Levin A.T., Hanage W.P., Owusu-Boaitey N., Cochran K.B., Walsh S.P., Meyerowitz-Katz G.. Assessing the age specificity of infection fatality rates for COVID-19: meta-analysis & public policy implications. 2020. Working paper 27597. National Bureau of Economic Research.

• Linden M.
• Dehning J.
• Mohr S.B.
• Mohring J.
• Meyer-Hermann M.
• Pigeot I.
• et al.
The foreshadow of a second wave: an analysis of current COVID-19 fatalities in germany.
arXiv. 2020;
3. Https://arxiv.org/abs/2010.05850
• Linton N.M.
• Kobayashi T.
• Yang Y.
• Hayashi K.
• Akhmetzhanov A.R.
• Sm J.
• et al.
Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data.
J Clin Med. 2020; 9: 538
• Lipsitch M.
• Donnelly C.A.
• Fraser C.
• Blake I.M.
• Cori A.
• Dorigatti I.
• et al.
Potential biases in estimating absolute and relative case-fatality risks during outbreaks.
PLoS Negl Trop Dis. 2015; 9: e0003846
• Lloyd-Sherlock P.
• Sempe L.
• McKee M.
• Guntupalli A.
Problems of data availability and quality for COVID-19 and older people in low- and middle-income countries.
Gerontologist. 2021; 61: 141-144
• Long Q.X.
• Tang X.J.
• Shi Q.L.
• Li Q.
• Deng H.J.
• Yuan J.
• et al.
Clinical and immunological assessment of asymptomatic SARS-cov-2 infections.
Nat Med. 2020; 26: 1200-1204
• Louca S.
• Astor Y.M.
• Doebeli M.
• Taylor G.T.
• Scranton M.I.
Microbial metabolite fluxes in a model marine anoxic ecosystem.
Geobiology. 2019; 17: 628-642
• Lu F.S.
• Nguyen A.T.
• Davis J.T.
• Chinazzi M.
• Xiong X.
• et al.
Estimating the cumulative incidence of COVID-19 in the united states using four complementary approaches.
medRxiv. 2020; https://doi.org/10.1101/2020.04.18.20070821
• Godfrey K.R.
• Chappell M.J.
• Hovorka R.
• Bates R.A.
A comparison of six deconvolution techniques.
J Pharmacokinet Biopharm. 1996; 24: 283-299
• Maugeri A.
• Barchitta M.
• Battiato S.
• Agodi A.
Estimation of unreported novel coronavirus (SARS-cov-2) infections from reported deaths: A susceptible–exposed–infectious–recovered–dead model.
J Clin Med. 2020; 9: 1350
• Maugeri A.
• Barchitta M.
• Battiato S.
• Agodi A.
Modeling the novel coronavirus (SARS-cov-2) outbreak in sicily, italy.
Int J Environ Res Public Health. 2020; 17: 4964
• Mendel J.M.
Maximum-likelihood deconvolution.
Springer, New York1990
• Merkely B.
• Szabó A.J.
• Kosztin A.
• Berényi E.
• Sebestyén A.
• C L.
• et al.
Novel coronavirus epidemic in the hungarian population, a cross-sectional nationwide survey to support the exit policy in hungary.
GeroScience. 2020; 42: 1063-1074
• Moore E.H.
On the reciprocal of the general algebraic matrix.
Bull Am Math Soc. 1920; 26: 394-395
• Murhekar M.
• Bhatnagar T.
• Selvaraju S.
• Saravanakumar V.
• Vivian Thangaraj J.
• et al.
Prevalence of SARS-cov-2 infection in india: Findings from the national serosurvey, may-june 2020.
Indian J Med Res. 2020; 152: 48-60
• Murhekar M.V.
• Bhatnagar T.
• Selvaraju S.
• Saravanakumar V.
• Thangaraj J.W.V.
• Shah N.
• et al.
SARS-cov-2 antibody seroprevalence in india, august–september, 2020: findings from the second nationwide household serosurvey.
Lancet Glob Health. 2021; 9: e257-e266
• Nah E.H.
• Cho S.
• Park H.
• Hwang I.
• Cho H.I.
Nationwide seroprevalence of antibodies to SARS-cov-2 in asymptomatic population in south korea: a cross-sectional study.
BMJ Open. 2021; 11: e049837
• Natashekara K.
COVID-19 cases in india and kerala: a benford’s law analysis.
J Public Health. 2021;
4. Fdab199
• Nguimkeu P.
Why is the number of COVID-19 cases lower than expected in sub-saharan africa? a cross-sectional analysis of the role of demographic and geographic factors.
World Dev. 2021; 138: 105251
• O’Driscoll M.
• Ribeiro Dos Santos G.
• Wang L.
• Cummings D.A.T.
• Azman A.S.
• Paireau J.
• et al.
Age-specific mortality and immunity patterns of SARS-cov-2.
Nature. 2021; 590: 140-145
• Ohia C.
• Bakarey A.S.
Covid-19 and nigeria: putting the realities in context.
Int J Infect Dis. 2020; 95: 279-281
• Pastor-Barriuso R.
• Pérez-Gómez B.
• Hernán M.A.
• Pérez-Olmeda M.
• Yotti R.
• Oteo-Iglesias J.
• et al.
Infection fatality risk for SARS-cov-2 in community dwelling population of spain: nationwide seroepidemiological study.
BMJ. 2020; 371: m4509
• Pearce N.
• Vandenbroucke J.P.
• VanderWeele T.J.
• Greenland S.
Accurate statistics on COVID-19 are essential for policy guidance and decisions.
Am J Public Health. 2020; 110: 949-951
• Penrose R.
A generalized inverse for matrices.
Proc Camb Philos Soc. 1955; 51: 406-413
• Poljak M.
• Oštrbenk Valenčak A.
• Štrumbelj E.
• Maver Vodičar P.
• Vehovar V.
• Resman Rus K.
• et al.
Seroprevalence of severe acute respiratory syndrome coronavirus 2 in slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned.
Clin Microbiol Infect. 2021; 27
5. 1039.e1–1039.e7
• Pollán M.
• Pérez-Gómez B.
• Pastor-Barriuso R.
• Oteo J.
• Hernán M.A.
• Pérez-Olmeda M.
• et al.
Prevalence of SARS-cov-2 in spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Lancet. 2020; 396: 535-544
• Reicher S.
• Ratzon R.
• Ben-Sahar S.
• Hermoni-Alon S.
• Mossinson D.
• Shenhar Y.
• et al.
Nationwide seroprevalence of antibodies against SARS-cov-2 in israel.
Eur J Epidemiol. 2021; 36: 727-734
• Riffe T.
• Acosta E.
• team t.C.D.
Data resource profile: COVerAGE-DB: a global demographic database of COVID-19 cases and deaths.
Int J Epidemiol. 2021; 50
6. 390–390f
• Rinaldi G.
An empirical estimate of the infection fatality rate of COVID-19 from the first italian outbreak.
medRxiv. 2020; https://doi.org/10.1101/2020.04.18.20070912
• Salje H.
• Tran Kiem C.
• Lefrancq N.
• Courtejoie N.
• Bosetti P.
• Paireau J.
• et al.
Estimating the burden of SARS-cov-2 in france.
Science. 2020; 369: 208-211
• Sánchez-Romero M.
• di Lego V.
• Prskawetz A.
• L. Queiroz B.
An indirect method to monitor the fraction of people ever infected with COVID-19: an application to the united states.
PLoS ONE. 2021; 16: e0245845
• Singh B.
International comparisons of COVID-19 deaths in the presence of comorbidities require uniform mortality coding guidelines.
Int J Epidemiol. 2021; 50: 373-377
• Snoeck C.J.
• Vaillant M.
• Abdelrahman T.
• Satagopam V.P.
• Turner J.D.
• Beaumont K.
• et al.
Prevalence of SARS-cov-2 infection in the luxembourgish population: the CON-VINCE study.
medRxiv. 2020; https://doi.org/10.1101/2020.05.11.20092916
• Soiza R.L.
• Scicluna C.
• Thomson E.C.
Efficacy and safety of COVID-19 vaccines in older people.
Age Ageing. 2021; 50: 279-283
• Vahidy F.S.
• Pischel L.
• Tano M.E.
• Pan A.P.
• Boom M.L.
• Sostman H.D.
• et al.
Real world effectiveness of COVID-19 mRNA vaccines against hospitalizations and deaths in the united states.
medRxiv. 2021; https://doi.org/10.1101/2021.04.21.21255873
• Veiga e Silva L.
• de Andrade Abi Harb M.D.P.
• Teixeira Barbosa dos Santos A.M.
• de Mattos Teixeira C.A.
• Macedo Gomes V.H.
• Silva Cardoso E.H.
• et al.
Covid-19 mortality underreporting in brazil: Analysis of data from government internet portals.
J Med Internet Res. 2020; 22: e21413
• Verotta D.
Two constrained deconvolution methods using spline functions.
J Pharmacokinet Biopharm. 1993; 21: 609-636
• Ward H.
• Atchison C.J.
• Whitaker M.
• Ainslie K.E.C.
• Elliott J.
• Okell L.C.
• et al.
Antibody prevalence for SARS-cov-2 in england following first peak of the pandemic: REACT2 study in 100,000 adults.
medRxiv. 2020;
7. 10.1101/2020.08.12.20173690
• Wiener N.
Extrapolation.
Ãnterpolation, and smoothing of stationary time series. MIT Press, Cambridge1964